Old Web
English
Sign In
Acemap
>
authorDetail
>
Gabor Kos
Gabor Kos
Medicine
Physical therapy
Doxorubicin
Topotecan
Cancer research
4
Papers
4
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Trends in oncology trials termination due to toxicity over a period of 16 years.
2018
Journal of Clinical Oncology
Laura Vidal
Kelly K. Curtis
Liat Vidal-Fisher
Gabor Kos
Keren Rachel Moss
Show All
Source
Cite
Save
Citations (0)
ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.
2018
Journal of Clinical Oncology
Anna F. Farago
Luis Paz-Ares
Tudor-Eliade Ciuleanu
Andrea Fülöp
Alejandro Navarro
Laura Bonanno
J. Lopez-Vilariño
Rafael Núñez
Carmen Kahatt
Gabor Kos
Arturo Soto Matos
Show All
Source
Cite
Save
Citations (4)
P2.04-008 ATLANTIS: Phase III Study of PM01183 with Doxorubicin vs. CAV or Topotecan in Small-Cell Lung Cancer After Platinum Therapy
2017
Journal of Thoracic Oncology
Anna F. Farago
Luis Paz-Ares
Andrea Fülöp
A. Chiappori
Konstantinos Syrigos
J. Lopez-Vilariño
Carmen Kahatt
Gabor Kos
Arturo Soto Matos
Show All
Source
Cite
Save
Citations (0)
Geographical distribution of industry driven clinical trials performed for leukemia over the last ten years.
2016
Journal of Clinical Oncology
Laura Vidal Boixader
Rob Jacobus Berg
Gabor Kos
Angel Uriol
Jim Wahl
Keren Rachel Moss
Show All
Source
Cite
Save
Citations (0)
1